A big decision for MedSafe, on whether to approve Johnson & Johnson's Covid-19 Janssen vaccine for use in New Zealand.
The medical regulator is due to make a recommendation on the vaccine today.
The US and Sweden are pausing use of the vaccine due to rare reports of blood-clotting, and the vaccine's roll-out across the rest of Europe has also been delayed.
Malaghan Institute vaccine expert Graham Le Gros told Kate Hawkesby MedSafe''s advice will focus on mitigating risk.
Meanwhile, Denmark has completely stopped the use of the AstraZeneca jab, due to similar reports of blood clotting.
No similar issues have been identified with the Pfizer vaccine, currently being rolled out in New Zealand.